Business Wars Daily Mounjaro Beats Ozempic in Study
Dec 6, 2023
A discussion on the effectiveness of terzepitide and semaglutide for weight loss, highlighting a study that found terzepitide to be significantly more effective. Analyzing the effectiveness of Munjaro and Ozempic for weight loss, discussing Eli Lilly's new drug Zepbound and Novo Nordisk's Wegovi, and highlighting the ongoing competition between the two companies.
AI Snips
Chapters
Transcript
Episode notes
Off-Label Use of Diabetes Drugs
- Ozempic and Mounjaro, popular for weight loss, are currently only approved for type 2 diabetes.
- Accessing them without this condition has become increasingly easy.
Comparing Ozempic and Mounjaro
- Ozempic (semaglutide) and Mounjaro (tirzepatide) work by decreasing appetite and increasing fullness.
- A new study aims to determine which drug is more effective for weight loss.
Mounjaro's Superiority in Weight Loss
- A study by TrueVetto Research found Mounjaro more effective for weight loss than Ozempic.
- Mounjaro users showed greater weight reduction after 3, 6, and 9 months.